Evidence map›Paper›PMID 37253744›Full record

ArticleNature communications2023

Antigen recognition detains CD8

Sidar Aydin, Javier Pareja, Vivianne M Schallenberg, Armelle Klopstein, Thomas Gruber, Nicolas Page, Elisa Bouillet, Nicolas Blanchard, Roland Liblau, Jakob Körbelin and 6 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. CD8Nature reviews. Cardiology · 2026
    Review
  9. Review
  10. Clonal CD8Nature immunology · 2026
    Article
  11. Targeting neuroinflammation in neurodegenerative disorders: the emerging potential of semaglutide.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2026
    Review
  12. Article
  13. CXCL10CNS neuroscience & therapeutics · 2026
    Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 4 countries.

Sidar Aydin *Theodor Kocher Institute, University of Bern, Bern, Switzerland.
Javier Pareja *Theodor Kocher Institute, University of Bern, Bern, Switzerland.
Vivianne M SchallenbergTheodor Kocher Institute, University of Bern, Bern, Switzerland.
Armelle KlopsteinTheodor Kocher Institute, University of Bern, Bern, Switzerland.
Thomas GruberInstitute of Pathology, Experimental Pathology, University of Bern, Bern, Switzerland.ORCID 0000-0001-5210-1995
Nicolas PageDepartment of Pathology and Immunology, Division of Clinical Pathology, University and University Hospitals of Geneva, Geneva, Switzerland.ORCID 0000-0002-5845-6831
Elisa BouilletTheodor Kocher Institute, University of Bern, Bern, Switzerland.ORCID 0000-0002-5405-6128
Nicolas BlanchardToulouse Institute for infectious and inflammatory diseases, University of Toulouse, CNRS, INSERM, UPS, Toulouse, France.ORCID 0000-0002-4924-2161
Roland LiblauToulouse Institute for infectious and inflammatory diseases, University of Toulouse, CNRS, INSERM, UPS, Toulouse, France.
Jakob KörbelinDepartment of Oncology, Hematology and Bone Marrow Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0002-5435-7182
Markus SchwaningerInstitute for Experimental and Clinical Pharmacology and Toxicology, Center of Brain, Behavior and Metabolism, University of Lübeck, Lübeck, Germany.ORCID 0000-0002-4510-9718
Aaron J JohnsonMayo Clinic Graduate School of Biomedical Sciences, College of Medicine, Mayo Clinic, Rochester, MN, USA.
Mirjam SchenkInstitute of Pathology, Experimental Pathology, University of Bern, Bern, Switzerland.ORCID 0000-0002-1637-0730
Urban DeutschTheodor Kocher Institute, University of Bern, Bern, Switzerland.
Doron MerklerDepartment of Pathology and Immunology, Division of Clinical Pathology, University and University Hospitals of Geneva, Geneva, Switzerland.ORCID 0000-0002-0247-2007
Britta EngelhardtTheodor Kocher Institute, University of Bern, Bern, Switzerland. britta.engelhardt@tki.unibe.ch.ORCID 0000-0003-3059-9846
University of Bern · CHCentre National de la Recherche Scientifique · FRUniversity Hospital of Geneva · CHMayo Clinic in Arizona · USUniversität Hamburg · DEUniversity of Lübeck · DE

Funding

CD8 T cell mediated disruption of Blood Brain Barrier Tight JunctionsR01NS103212 · NINDS · MAYO CLINIC ROCHESTER · PI Aaron J Johnson · 2017 to 2026
$4.6M
Defining MHC class I restricted antigen presentation to CD8 T cells in experimental AD and Tauopathy - SupplementRF1NS122174 · NINDS · MAYO CLINIC ROCHESTER · PI JOHNSON, AARON J · 2021 to 2023
$2.0M
NINDS NIH HHS R01 NS103212NINDS NIH HHS RF1 NS122174
6 · The paper itself

Abstract

Blood-brain barrier (BBB) breakdown and immune cell infiltration into the central nervous system (CNS) are early hallmarks of multiple sclerosis (MS). High numbers of CD8

Indexed as

Blood-Brain BarrierMultiple SclerosisCD8-Positive T-LymphocytesCentral Nervous SystemEndothelial CellsHistocompatibility Antigens Class IHumansHistocompatibility Antigens Class I

Identifiers

PMID37253744
PMCPMC10229608
OpenAlexW4378713677

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.